Filing Flows › Conmed (CNMD) › Guidance & outlook
Conmed (CNMD) guidance and outlook
Conmed (CNMD) reaffirmed its guidance on Oct 28, 2026: Revenue −1.7% for ; EPS −$4.00 for . Conmed's 10-Q filed Apr 30, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | −1.7% | reaffirmed | |
| Revenue | +5% | new | |
| EPS | −$4.00 | reaffirmed |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Apr 30, 2026
- We will continue to monitor and adjust, if necessary, our business strategy in response to the conflicts in these regions.
- Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our eighth amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, and common stock repurchases in the foreseeable future.
- We intend to secure incremental financing to fund the maturity of the 2.250% Convertible Notes.
- There can be no assurance we will be able to obtain such financing on acceptable terms.
- If we are unable to service our indebtedness, we will be forced to adopt an alternative strategy that may include actions such as foregoing acquisitions, reducing or delaying capital expenditures, selling assets, restructuring or refinancing our indebtedness or seeking additional equity capital.
- The Company expects to repurchase at least $25.0 million in shares annually with $61.8 million
Conmed's latest quarter
Conmed, Q3 2026: revenue $336M (-0.7% year over year), operating margin 11.1%, net earnings $19.8M, operating cash flow $49.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Conmed raise or lower its guidance?
Conmed (CNMD) reaffirmed its guidance on Oct 28, 2026: Revenue −1.7% for ; EPS −$4.00 for .
What does Conmed expect?
We will continue to monitor and adjust, if necessary, our business strategy in response to the conflicts in these regions. Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our eighth amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, and common stock repurchases in the foreseeable future. We intend to secure incremental financing to fund the maturity of the 2.250% Convertible Notes.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.